daiichi sankyo company , limited ( 第一三共株式会社 daiichi sankyō kabushiki-kaisha ) is a global pharmaceutical company and the second largest pharmaceutical company in japan .

it achieved jpy 1,148.2 billion in revenue in 2013 .

the company owns the american biotechnology company plexxikon , the german biotechnology company u3 pharma and recently sold ranbaxy laboratories in india .

daiichi sankyo co. , ltd. is the producer of benicar ( olmesartan ) , an angiotensin ii receptor antagonist and top selling drug in the u.s. global sales of olmesartan in 2013 were 300.2 billion yen .

daiichi sankyo , inc. ( dsi ) began operating in the u.s. in 2006 .

it is the u.s. subsidiary of daiichi sankyo , company , limited and a member of the daiichi sankyo group .

the organization , which includes u.s. commercial operations and global clinical development ( daiichi sankyo pharma development ) , is headquartered in parsippany , new jersey .

daiichi sankyo europe , gmbh ( dse ) , the european subsidiary , is headquartered in munich , germany .

daiichi sankyo company , limited is a full member of the european federation of pharmaceutical industries and associations ( efpia ) and of the international federation of pharmaceutical manufacturers and associations ( ifpma ) .

in 2009 , the highly respected magazine r&d direction honoured daiichi sankyo with its " best cardiovascular pipeline award " .

daiichi sankyo

began operations of daiichi sankyo healthcare co . , ltd . ; daiichi sankyo , inc . ; and daiichi sankyo europe gmbh
daiichi and sankyo announce their agreement to merge , establishing daiichi sankyo co . , ltd . in japan
daiichi pharmaceutical co . , ltd . and sankyo co . , ltd . integrate to form daiichi sankyo , inc .
daiichi sankyo , inc . announces sale of pharmaceutical packaging plant in bethlehem , pa - media & investors - daiichi sankyo
daiichi sankyo is the joint holding company established in 2005 by sankyo co and and daiichi pharmaceuticals , both based out of japan .
established in 2005 through the merger of daiichi pharmaceutical and sankyo , daiichi sankyo has a rich history spanning more than 100 years .
sankyo and daiichi establish a joint holding company in japan named daiichi sankyo company , limited . the european merger follows one year later .
the daiichi sankyo corporate governance report has been updated . read more . . .
began operations on april 1 , 2007 as daiichi sankyo co . , ltd .
a pedestrian passes daiichi sankyo inc . ' s headquarters in tokyo . | bloomberg
daiichi sankyo was not approached by anglo - swedish drugmaker astrazeneca over a takeover .
daiichi - sankyo website 211 mt . airy road , basking ridge , nj 07920
daiichi sankyo , inc . announces sale of pharmaceutical packaging plant in bethlehem , pa
a collaboration to jointly investigate novel therapeutic candidates to further strengthen daiichi sankyo’s pipeline .
daiichi sankyo enters into a worldwide licensing agreement for daiichi sankyo’s novel ret inhibitor , ds - 5010 . under the terms of the agreement , daiichi sankyo grants boston pharmaceuticals worldwide rights for the research , development , manufacturing and commercialization of ds - 5010
established wholly - owned subsidiary daiichi sankyo ( china ) holdings co . , ltd .
sankyo buys out sankyo parke - davis , combining all u . s . commercial operations , research and development into one organization , sankyo pharma inc
daiichi sankyo to pay $ 39 million to settle u . s . kickback claims : doj
daiichi sankyo , inc . began operating in the u . s . in 2006 . it is the u . s . subsidiary of daiichi sankyo , co . , ltd and a member of the daiichi sankyo group . the organization , which includes u . s . commercial operations and global clinical development ( daiichi sankyo pharma development ) , is headquartered in new jersey .
daiichi sankyo enters into strategic collaboration with agonox , inc . to develop undisclosed immune - oncology target
mahmoud ghazzi , m . d . , ph . d . , daiichi sankyo , co .
the new daiichi sankyo group’s value report is now available ! the report includes business facts & figures , information about daiichi sankyo’s growth potential , csr activities and much more . read more . . .
daiichi sankyo is a global pharmaceutical company with its corporate origin in japan . read more . . .
daiichi sankyo healthcare acquired mail - order cosmetics and health food business , im co . , ltd .
daiichi sankyo , inc . acquires first u . s . - based packaging facility , located in pennsylvania
to strengthen its oncology pipeline , daiichi sankyo acquires the biotech company u3 pharma in martinsried , germany .
daiichi sankyo to pay $ 39 million to settle u . s . kickback claims : doj | reuters
sankyo is the first company to isolate epinephrine , discovered by sankyo ' s first president , dr . jokichi takamine
established by joint holding company of sankyo co . , ltd . and daiichi pharmaceutical co . , ltd .
tokyo , japan ( july 1 , 2015 ) – daiichi sankyo company , limited today announced that its affiliated foundation , the daiichi sankyo foundation of life science * ( headquarters , tokyo ; chairman , joji nakayama ) has awarded its 13th takamine memorial daiichi sankyo prize to hidenori ichijo , professor , tokyo university graduate school of pharmaceutical sciences .
daiichi sankyo presents phase 3 enliven study of pexidartinib , demonstrating statistically significant clinical improvement across multiple endpoints . . .
daiichi sankyo settles u . s . lawsuits over intestinal damage from blood - pressure drugs , paying $ 300 million
daiichi sankyo hong kong will strive to serve the local medical needs of the community . read more . . .
phase 3 quantum - r study demonstrates daiichi sankyo’s quizartinib significantly prolongs overall survival as single agent compared to chemotherapy in . . .
daiichi sankyo ' s mission is to create innovative medicines that improve people’s health and quality of life . read more . . .
after the big earthquake and the tsunami in japan daiichi sankyo europe offers strong support to its colleagues in japan . the company also launches an aid initiative called “daiichi sankyo children aid” . this is to help japanese children severely affected by the earthquake disaster . .
daiichi sankyo ' s share price was up 5 percent when trading was suspended . astrazeneca was little changed in early london trade .
tokyo ; basking ridge , n . j . ; and cambridge , mass . , aug . 28 , 2017 / prnewswire / - - daiichi sankyo company , limited ( hereafter , daiichi sankyo ) and boston pharmaceuticals , inc . ( hereafter , boston pharmaceuticals ) today announced they have entered into a worldwide licensing agreement for daiichi sankyo ' s novel ret inhibitor , ds - 5010 .
daiichi sankyo settles u . s . lawsuits over intestinal damage from blood - pressure drugs , paying $ 300 million | the japan times
new york & tokyo - - ( business wire ) - - bristol - myers squibb company ( nyse : bmy ) and daiichi sankyo company , limited ( hereafter , daiichi sankyo ) today announced a collaborative clinical trial to evaluate the combination of bristol - myers squibb’s immunotherapy opdivo ( nivolumab ) and daiichi sankyo’s investigational antibody drug conjugate ds - 8201 in her2 - expressing metastatic breast and urothelial ( bladder ) cancers .
daiichi sankyo is a large global pharmaceutical company and the second largest drug maker in japan . headquartered in tokyo , this company has been around only since a 2005 merger between dankyo company , limited , and daiichi pharmaceutical company , limited . daiichi sankyo also owns several smaller companies around the world , including plexxikon in the u . s .
environment value : daiichi sankyo ( thailand ) ltd . had conducted plantation activity at klong kone , samutsongkram ( nov . 1 , 2014 )
looking for a job at daiichi sankyo uk ? we offer opportunities for your personal career in an international environment . read more . . .
daiichi sankyo acquires the biopharmaceutical company ambit biosciences . at our german plant in pfaffenhofen near munich a new building for pharmaceutical development is inaugurated providing
looking for a job at daiichi sankyo europe ? we offer opportunities for your personal career in an international environment . read more . . .
japan’s daiichi sankyo has been wielding the ax over the past quarter to half a dozen pipeline medications across cancer , diabetes and cv disease .
daiichi sankyo , inc . jennifer brennan jbrennan2 @ urltoken + 1 908 992 6631 ( office ) + 1 201 709 9309 ( mobile )
the history of daiichi sankyo begins with the founding of sankyo company , limited in 1899 . the business began with a digestive enzyme and an adrenalin product . an early success for the company was the discovery of vitamin b1 in 1910 . daiichi pharmaceuticals company , limited was founded in 1915 . daiichi’s early products included drugs for treating syphilis and asthma .
daiichi sankyo and puma biotechnology enter into a preclinical research collaboration with memorial sloan kettering cancer center ( msk ) to explore the combination of daiichi sankyo’s investigational antibody drug conjugate ds - 8201 and puma biotechnology’s irreversible pan - her inhibitor neratinib in her2 - mutated or her2 - positive solid tumors .
the daiichi sankyo oncology portfolio continues to grow and currently includes both small molecules and monoclonal antibodies with novel targets in both solid and hematologic cancers .
daiichi sankyo said last year its cancer pipeline had more than 20 small molecules and monoclonal antibodies with novel targets in both solid and hematological cancers .
daiichi sankyo is a global pharmaceutical company with corporate origins in japan . we provide innovative products and services in more than 20 countries around the world .
daiichi sankyo europe is founded as the new european headquarters on 1 july 2006 in munich . business activities in the united kingdom and germany are integrated .
daiichi sankyo , which has a market value of about $ 16 billion , declined the offer , the online version of nikkei business reported citing unidentified sources .
sankyo acquires luitpold - werk and thus gains a presence in europe and latin america .
about daiichi sankyo daiichi sankyo group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified , unmet medical needs of patients in both mature and emerging markets . with over 100 years of scientific expertise and a presence in more than 20 countries , daiichi sankyo and its 15 , 000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people . in addition to a strong portfolio of medicines for hypertension and thrombotic disorders , under the group’s 2025 vision to become a “global pharma innovator with competitive advantage in oncology , ” daiichi sankyo research and development is primarily focused on bringing forth novel therapies in oncology , including immuno - oncology , with additional focus on new horizon areas , such as pain management , neurodegenerative diseases , heart and kidney diseases , and other rare diseases . for more information , please visit : urltoken . daiichi sankyo , inc . , headquartered in basking ridge , new jersey , is a member of the daiichi sankyo group . for more information on daiichi sankyo , inc . , please visit : urltoken .
about daiichi sankyo daiichi sankyo group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified , unmet medical needs of patients in both mature and emerging markets . with over 100 years of scientific expertise and a presence in more than 20 countries , daiichi sankyo and its 15 , 000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people . in addition to a strong portfolio of medicines for hypertension and thrombotic disorders , under the group ' s 2025 vision to become a
global pharma innovator with competitive advantage in oncology ,
daiichi sankyo research and development is primarily focused on bringing forth novel therapies in oncology , including immuno - oncology , with additional focus on new horizon areas , such as pain management , neurodegenerative diseases , heart and kidney diseases , and other rare diseases . for more information , please visit : urltoken . daiichi sankyo , inc . , headquartered in basking ridge , new jersey , is a member of the daiichi sankyo group . for more information on daiichi sankyo , inc . , please visit : urltoken .
daiichi sankyo to present late - breaking phase 3 data for single agent quizartinib in patients with relapsed / refractory aml with flt3 - itd mutations at . . .
daiichi sankyo europe , ghbh , the european subsidiary , is headquartered in munich , germany . the organization is responsible for development and manufacturing for 12 european countries .
as the u . s . subsidiary of a global pharmaceutical innovator , daiichi sankyo , inc . draws on a rich heritage of innovation , integrity and accountability .
at daiichi sankyo , the japanese drugmaker earlier this year said it would spend 15 billion yen ( $ 136 million ) to raise production of antibody drug conjugates .
daiichi sankyo is committed to responsibly bringing opioid and non - opioid medicines to the many patients in need of treatment to help alleviate pain . read more . . .
the core focus of the program will be on the daiichi sankyo , inc . internal pipeline and business development opportunities in areas such as oncology , pain and specialty therapeutics .
daiichi sankyo is a global pharmaceutical company striving to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals . read more . . .
on november 1st , 2014 , daiichi sankyo ( thailand ) ltd . had conducuted plantation activity for the better environment and raising awareness among staff on global warming protection at klong kone
the vision of daiichi sankyo cancer enterprise is to leverage our world - class , innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer .
daiichi sankyo group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified , unmet medical needs of patients in both mature and emerging markets . with over 100 years of scientific expertise and a presence in more than 20 countries , daiichi sankyo and its 15 , 000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people . in addition to a strong portfolio of medicines for hypertension and thrombotic disorders , under the group’s 2025 vision to become a “global pharma innovator with competitive advantage in oncology , ” daiichi sankyo research and development is primarily focused on bringing forth novel therapies in oncology , including immuno - oncology , with additional focus on new horizon areas , such as pain management , neurodegenerative diseases , heart and kidney diseases , and other rare diseases . for more information , please visit : urltoken . daiichi sankyo , inc . , headquartered in basking ridge , new jersey , is a member of the daiichi sankyo group . for more information on daiichi sankyo , inc . , please visit : urltoken .
daiichi sankyo co . , ltd . was established in 2005 with the merger of two leading century - old pharmaceutical companies , daiichi pharmaceutical co . , ltd . and sankyo co . , ltd . daiichi sankyo maintains a portfolio of marketed pharmaceuticals for hypertension , hyperlipidemia , and bacterial infections around the world and also focuses on the discovery of novel oncology therapies . headquartered in tokyo , the company is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified , unmet medical needs of patients in both mature and emerging markets .
the case is captioned u . s . ex rel . fragoules v . daiichi sankyo , inc . , civil action no . 10 - 10420 ( d . mass . ) .
a man walks past a sign of japanese pharmaceutical company daiichi sankyo co . , ltd . at the company ' s head office in tokyo july 17 , 2009 . reuters / stringer
the case is u . s . ex rel . fragoules v . daiichi sankyo inc , u . s . district court , district of massachusetts , no . 10 - 10420 .
daiichi sankyo inc . has settled thousands of lawsuits alleging its blood - pressure drugs caused intestinal damage , bringing to $ 339 million the amount the drugmaker has paid over the medicines .
daiichi sankyo group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified , unmet medical needs of patients in both mature and emerging markets . with over 100 years of scientific expertise and a presence in more than 20 countries , daiichi sankyo and its 16 , 000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people . in addition to a strong portfolio of medicines for hypertension and thrombotic disorders , under the group ' s 2025 vision to become a
global pharma innovator with a competitive advantage in oncology ,
daiichi sankyo research and development is primarily focused on bringing forth novel therapies in oncology , including immuno - oncology , with additional focus on new horizon areas , such as pain management , neurodegenerative diseases , heart and kidney diseases , and other rare diseases . for more information , please visit : urltoken . daiichi sankyo , inc . , headquartered in parsippany , new jersey , is a member of the daiichi sankyo group . to learn more about daiichi sankyo , inc . , please visit urltoken .
daiichi sankyo group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified , unmet medical needs of patients in both mature and emerging markets . with over 100 years of scientific expertise and a presence in more than 20 countries , daiichi sankyo and its 16 , 000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people . in addition to a strong portfolio of medicines for hypertension and thrombotic disorders , under the group ' s 2025 vision to become a
global pharma innovator with competitive advantage in oncology ,
daiichi sankyo research and development is primarily focused on bringing forth novel therapies in oncology , including immuno - oncology , with additional focus on new horizon areas , such as pain management , neurodegenerative diseases , heart and kidney diseases , and other rare diseases . for more information , please visit : urltoken . daiichi sankyo , inc . , headquartered in parsippany , new jersey , is a member of the daiichi sankyo group . for more information on daiichi sankyo , inc . , please visit : urltoken .
daiichi sankyo and arqule acknowledged today that arqule’s lead product , the hepatocellular carcinoma ( hcc ) candidate tivantinib ( arq 197 ) , has failed the phase iii metiv - hcc trial .
“we are very excited by the rapid progress we have made in our collaboration with daiichi sankyo , which further demonstrates the versatility and biophysical robustness of the azymetric™ platform , and we continue to work closely with daiichi sankyo towards advancing this potential immuno - oncology therapeutic towards the clinic , ” said dr . ali tehrani , president and ceo of zymeworks . “in parallel , we are continuing to develop and advance other novel immunomodulatory bispecific antibodies incorporating the immuno - oncology antibodies that were in - licensed from daiichi sankyo to expand zymeworks’ pipeline of therapeutic candidates . ”
the lawsuit claimed daiichi sankyo inc paid kickbacks to doctors in the form of speaking fees at programs it hosted from 2004 until 2011 . the doctors were sometimes even paid for speaking only to their own staff over “lavish” dinners hosted by daiichi , according to the doj .
as the u . s . subsidiary of a global pharmaceutical innovator , daiichi sankyo , inc . draws on a rich heritage of innovation , integrity and accountability . read more . . .
the study is expected to begin enrollment in first quarter of 2018 in the us and europe . under the terms of the agreement , daiichi sankyo will be the sponsor conducting the trial .
launched urief® , a drug for dysuria ( daiichi pharmaceutical co . , ltd . )
parsippany , nj – april 3 , 2017 – daiichi sankyo , inc . ( “the company” ) announced today that sharp packaging services , a division of udg healthcare , plc ( “sharp” ) has purchased the daiichi sankyo pharmaceutical packaging plant located in bethlehem , pa ( “the plant” ) . the transaction closed on april 1 , 2017 , at which time sharp took over operations at the plant . sharp is now packaging several of daiichi sankyo , inc . medications in bethlehem . sharp has also offered the plant’s workers opportunities for employment . detailed financial terms are not being disclosed .
daiichi sankyo in ireland was officially inaugurated at the end of 2008 , initially as a sales and marketing operation but has since added medical , finance and administration functions . read more . . .
under the terms of the agreement , daiichi sankyo grants boston pharmaceuticals worldwide rights for the research , development , manufacturing and commercialization of ds - 5010 . daiichi sankyo will collaborate with boston pharmaceuticals to complete preclinical studies to support an investigational new drug application to regulatory authorities and initiation of the clinical program , after which boston pharmaceuticals will be responsible for all activities related to ds - 5010 . daiichi sankyo will receive an upfront payment and is eligible for clinical , regulatory and sales milestone payments , as well as royalties on net sales worldwide . financial terms of the agreement were not disclosed .
nakayama noted that daiichi sankyo has built its cancer portfolio in part through earlier acquisitions : in 2011 , daiichi sankyo acquired plexxikon for $ 805 million upfront , plus another $ 130 million in milestone payments tied to approvals for zelboraf ( vemurafenib ) , an oral treatment co - developed with roche for the braf mutation present in about half of melanoma cancers , and about 8 % of solid tumors .
last week , the wall street journal reported that manufacturer daiichi sankyo agreed to settle a lawsuit for $ 39 million after it was accused of paying kickbacks to physicians to prescribe several of its drugs .
daiichi sankyo was accused of encouraging doctors to prescribe welchol , a cholesterol - lowering medication , and benicar , azor , and tribenzor , which are high blood pressure pills , according to the journal .
under the terms of the partnership agreement , daiichi sankyo will be responsible for development and commercialization of axicabtagene ciloleucel in japan . daiichi sankyo will make an upfront payment to kite of $ 50 million and kite will be eligible to receive future payments totaling up to $ 200 million for development and commercial milestones . kite is also entitled to receive sales royalties in the low to mid double digit range .
daiichi sankyo agreed to pay $ 39 million to the u . s . federal government and state medicaid programs to settle allegations of paying kickbacks to physicians to prescribe several of its drugs . the agreement , which is the latest in a string of such deals in recent years involving drug makers , stems from a lawsuit filed under whistleblower provisions of the false claims act by a former daiichi sankyo sales rep .
astrazeneca may have targeted daiichi sankyo for its expertise in antibody drug conjugates , a new kind of
armed antibody
that can carry a cancer - killing payload to tumour cells , the magazine reported .
vancouver , british columbia , tokyo and basking ridge , n . j . - - ( business wire ) - - zymeworks inc . ( “zymeworks” ) , a clinical - stage biopharmaceutical company dedicated to the discovery , development and commercialization of next - generation bispecific and multifunctional biotherapeutics , initially focused on the treatment of cancer , and daiichi sankyo company , limited ( “daiichi sankyo” ) today announced the successful achievement of a research milestone for an immuno - oncology bispecific antibody therapeutic candidate in their collaboration . in conjunction with this milestone achievement , zymeworks is to receive a milestone payment of one million dollars from daiichi sankyo .
one of the company’s most successful drugs has been benicar for high blood pressure . it is one the company’s best - selling prescription medication in the u . s . other drugs made by daiichi sankyo include mevalotin , for lowering cholesterol , loxonin , a painkiller , and cravit , an antibiotic . in spite of its successes , daiichi sankyo has also faced setbacks , including harmful products and allegations of providing kickbacks .
daiichi sankyo will acquire ambit biosciences for up to about $ 410 million , the companies said today , in a deal that adds ambit’s lead candidate—the phase iii cancer compound quizartinib—to the buyer’s portfolio of personalized oncology drugs .
our company was founded in 2006 through the merger of the well - established japanese companies daiichi and sankyo in europe . daiichi sankyo is a global pharmaceutical company based in japan that has a presence in more than 20 countries around the world . with a rich legacy of over 100 years of scientific expertise , we are the pioneer behind leading pharmaceuticals that have contributed to the improvement of countless lives . our global headquarters is in tokyo .
daiichi sankyo agreed to pay ambit shareholders approximately $ 315 million upfront through a tender offer followed by a merger with a daiichi sankyo subsidiary , plus one contingent value right ( cvr ) valued at up to $ 4 . 50 cash for each share owned , tied to unspecified commercialization - related milestones . at $ 15 per share , the upfront portion reflects an 83 % premium to ambit’s closing share price of $ 8 . 20 on september 26 .
tokyo , japan and san diego , ca ( september 28 , 2014 ) - daiichi sankyo company , ltd . ( hereinafter daiichi sankyo ) ( tse : 4568 ) and ambit biosciences ( nasdaq : ambi ) , jointly announced today that they have entered into a definitive merger agreement under which daiichi sankyo will acquire all of the outstanding common stock of ambit biosciences for $ 15 per share in cash through a tender offer followed by a merger with a subsidiary of daiichi sankyo , or approximately $ 315 million on a fully diluted basis . in addition to the upfront cash payment , each ambit biosciences stockholder will receive one contingent value right ( cvr ) , entitling the holder to receive an additional cash payment of up to $ 4 . 50 for each share they own if certain commercialization related milestones are achieved . the total transaction is valued at up to $ 410 million on a fully diluted basis .
daiichi did not agree to sever the financial incentive structure for its sales representatives . the cia states :
zymeworks : david poon , ph . d . executive director , external r & d and alliances ( 604 ) 678 - 1388 bd @ urltoken or investor inquiries : david matousek senior manager , investor relations & corporate communications ( 604 ) 678 - 1388 ir @ urltoken or daiichi sankyo : jennifer brennan director , global product communications daiichi sankyo , inc . + 1 908 992 6631 ( office ) + 1 201 709 9309 ( mobile ) jbrennan2 @ urltoken
daiichi sankyo group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified , unmet medical needs of patients in both mature and emerging markets . while maintaining its portfolio of marketed pharmaceuticals for hypertension , dyslipidemia and bacterial infections used by patients around the world , the group has also launched treatments for thrombotic disorders and is building new product franchises . furthermore , daiichi sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular - metabolic diseases , including biologics . the daiichi sankyo group has created a
hybrid business model ,
to respond to market and customer diversity and optimize growth opportunities across the value chain . for more information , please visit : urltoken .
the fda also issued a warning to daiichi sankyo , stating that the company had aggressively marketed the drug , knowing the problems that could arise with gastrointestinal symptoms . the company was accused of being misleading about the benefits and risks of benicar .
here , the government alleged that daiichi paid physicians improper kickbacks in the form of speaker fees as part of daiichi sankyo’s physician organization and discussion programs , known as “pods , ” from jan . 1 , 2005 , through march 31 , 2011 , as well as other speaker programs from jan . 1 , 2004 , through feb . 4 , 2011 .
japanese pharmaceutical company , daiichi sankyo inc . , with u . s . headquarters in new jersey , has agreed to pay $ 39 million to resolve allegations that it violated the false claims act . the complaint alleges that daiichi marketed a number of its hypertension and diabetes drugs off - label , and paid kickbacks to induce physicians to prescribe them . a former daiichi sales representative initially brought the complaint , and will get $ 6 . 1 million from the settlement .
daiichi sankyo , inc . , headquartered in basking ridge , nj , is the u . s . subsidiary of daiichi sankyo co . , ltd . , a global pharmaceutical company . the company was formed in 2006 from the integration of two leading pharmaceutical companies , sankyo co . , ltd . and daiichi pharmaceutical co . , ltd . our team of nearly 1 , 400 u . s . employees is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified , unmet medical needs of patients in both mature and emerging markets . with over 100 years of scientific expertise and a presence in more than 20 countries , daiichi sankyo and its 15 , 000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people . in addition to a strong portfolio of medicines for hypertension and thrombotic disorders , under the group’s 2025 vision to become a “global pharma innovator with a competitive advantage in oncology , ” daiichi sankyo research and development is primarily focused on bringing forth novel therapies in oncology , including immuno - oncology , with additional focus on new horizon areas , such as pain management , neurodegenerative diseases , heart and kidney diseases , and other rare diseases .
centerview partners acted as lead financial advisor to ambit biosciences . leerink partners llc also acted as financial advisor to ambit biosciences . cooley llp acted as legal advisor to ambit biosciences . simpson thacher & bartlett llp acted as legal advisor to daiichi sankyo .
ranbaxy valued at $ 8 . 8 billion with daiichi paying rs737 per share at 70 % premium to market cap
in addition to the $ 39 million payment , daiichi has agreed to make internal reforms , the doj said .
for the last nine years daiichi sankyo has supported young graduates in pharmaceutical sciences from the ludwig - maximilians - university in munich ( lmu ) . in 2017 , kristina eiglmeier and martin müller were awarded the
master prize
read more . . .
in addition , daiichi sankyo lays the foundation for further growth in europe by acquiring the marketing rights for the osteoporosis drug evista ® ( with the active ingredient raloxifene ) from eli lilly and company , and by establishing new affiliates in istanbul and dublin .
another big controversy that daiichi sankyo has faced is over kickbacks related to benicar and other drugs . according to the u . s . department of justice ( doj ) , the company held a series of physician organization and discussion programs , or pods , between 2005 and 2011 . physicians were paid speaker fees for the pods , even when they didn’t really give a talk , or only spoke to their own staff . they were also given lavish dinners that exceeded daiichi sankyo’s own imposed limits on spending .
“quizartinib will fit seamlessly into our already robust oncology pipeline focused on targeted therapies with the potential for personalizing the treatment of cancer , ” said mahmoud ghazzi , md , phd , global head of development for daiichi sankyo . “with the acquisition of ambit biosciences , daiichi sankyo gains additional opportunities to develop promising treatments for cancer , including the global rights to quizartinib , currently being studied in patients with refractory aml , a very serious condition for which no new therapies have been approved for more than 30 years . ”
tokyo ( reuters ) - britain ' s astrazeneca plc offered to buy peer daiichi sankyo co ltd last year , a business magazine reported on thursday , sending the japanese drugmaker ' s share price soaring as much as 13 percent and triggering a trade suspension .
daiichi sankyo inc . , a global pharmaceutical company with its u . s . headquarters in new jersey , has agreed to pay the united states and state medicaid programs $ 39 million to resolve allegations that it violated the false claims act by paying kickbacks to induce physicians to prescribe daiichi drugs , including azor , benicar , tribenzor and welchol , the justice department announced today .
“long - term success in oncology depends upon three pillars : fostering development of our in - house molecules , exploring mutually beneficial partnerships and executing strategic purchases , such as ambit biosciences , ” joji nakayama , daiichi sankyo’s president and ceo , said in a statement .
as daiichi sankyo , inc . continues to re - orient its business focus towards the specialized areas of oncology and pain , it is moving to an outsourced packaging model for its medications as part of its ongoing efforts to stay flexible and aligned with customer demands .
under the terms of their existing agreement signed on september 26 , 2016 , zymeworks granted daiichi sankyo a license to zymeworks’ azymetric™ and efect™ platforms to develop a bispecific antibody therapeutic for which zymeworks is eligible to receive preclinical , clinical and commercial milestone payments , as well as up to double - digit tiered royalties on global product sales . additionally , zymeworks obtained a license to certain immuno - oncology antibodies from daiichi sankyo , with the right to research , develop and commercialize multiple bispecific products globally in exchange for royalties on global product sales .
daiichi also must make disclosures consistent with the federal sunshine act available on its website and make extensive grant disclosure as well .
as we have reported previously in our blog , benicar and other drugs with antihypertensive agents have been linked to complications , including severe intestinal sprue - like enteropathy , a condition similar to celiac disease . this makes the fact that daiichi sankyo was accused of promoting kickbacks alarming .
* since its establishment in 1983 , the daiichi sankyo foundation of life sciences has provided support for innovative research in the life sciences . the foundation also sponsors international symposia and supports exchange programs that allow foreign academics to visit japan and japanese researchers to complete short terms of work overseas .
daiichi sankyo continues to build on dr . takamine ' s legacy by contributing to the communities where we live and work . we honor dr . takamine ' s legacy today through philanthropic and volunteer efforts that include support for science , education and access to medical care across the globe .
three years earlier , daiichi sanko snapped up germany’s u3 pharma for €150 million ( $ 235 million at the time but $ 190 . 5 million today ) . that deal boosted daiichi sankyo’s pipeline with u3’s lead product—patritumab ( u3 - 1287 / amg 888 ) , a fully human anti - her3 monoclonal antibody designed to inhibit oncogenic signaling and tumor proliferation , co - developed with amgen and now in phase ii trials .
daiichi sankyo ' s heritage of scientific discovery spans 110 years – from the discovery of epinephrine ( also known as adrenaline ) and the development of the statin class of lipid - lowering agents to the development of the first glitazone , which revolutionized long - term control of type 2 diabetes .
“despite the negative outcome of this study , we remain committed to applying rigorous science to unmet needs for patients with cancer , ” antoine yver , m . d . , m . sc . , evp and global head , oncology research and development , daiichi sankyo , said in a statement .
( reuters ) - the u . s . subsidiary of global pharmaceutical company daiichi sankyo co ltd has agreed to pay $ 39 million to the u . s . government and state medicaid programs to settle claims it paid doctors kickbacks to prescribe its drugs , the department of justice said on friday .
japanese drugmaker daiichi sankyo is to spend ¥500 billion ( $ 4 . 4 billion ) on mergers and acquisitions with a major new focus on buying up cancer drugs . the plans come as the company looks to shore up the losses from its blockbuster hypertension drug , set to decimate its balance sheet .
sankyo launches olmesartan , a strategic global product for the treatment of hypertension . it is promoted as olmetec ® in europe and as benicar ® in the united states .
as part of the transaction , kite will provide certain technical transfer services to daiichi sankyo . in addition , daiichi sankyo has a certain period of time to license additional kite product candidates for japan including kite - 718 , kite ' s t cell receptor product candidate targeting mage - a3 / a6 and certain other product candidates that proceed to a u . s . investigational new drug application filing over the next three years . upfront and milestone payments for each additional product candidate could equal up to $ 200 million plus low to mid double digit sales royalties . kite retains all development and commercialization rights outside of japan .
sales reps were allegedly trained to use various reprints to promote off - label , and used kickbacks to encourage doctors to prescribe daiichi’s products .
to further expand our company’s european presence , sankyo acquires paris - based laboratories fornet in 2002 and gaines access to the french market , one of europe’s major pharmaceutical markets .
new york – attorney general eric t . schneiderman today announced that new york , along with 49 other states and the district of columbia have reached a settlement with daiichi sankyo , inc . ( daiichi ) , a global pharmaceutical company with us headquarters in new jersey . the settlement resolves allegations that daiichi violated the false claims act by using lavish meals and speaker programs to improperly induce physicians to prescribe the drugs azor , benicar , tribenzor and welchol . under the agreement , daiichi agrees to pay the united states and the state medicaid programs 39 million dollars , 10 million dollars to the state medicaid programs and 19 million to other federal programs . under this agreement , the new york state medicaid program will receive $ 2 , 339 , 671 .
the settlement also resolves claims against forest laboratories inc . , which sold benicar and other daiichi blood - pressure medicines in the u . s .
company name : daiichi sankyo company , limited representative : joji nakayama , representative director , president and ceo ( code no . : 4568 , first section , tokyo stock exchange ) please address inquiries to noriaki ishida , executive officer , vice president , corporate communications department telephone : + 81 - 3 - 6225 - 1126 urltoken
sankyo and daiichi merged in 2005 and jointly worked on a flu vaccine , effient , an antiplatelet agent , memary for the treatment of alzheimer’s disease , and nexium in partnership with astrazeneca . over the years the companies have also acquired a number of other , smaller companies , like zepharma , ranbaxy , and u3 pharma .
company name : daiichi sankyo company , limited representative : joji nakayama , representative director , president and ceo ( code no . : 4568 , first section , tokyo stock exchange ) please address inquiries to noriaki ishida , corporate officer , vice president , corporate communications department telephone : + 81 - 3 - 6225 - 1126 urltoken
this press release contains forward - looking statements . any statements contained herein which do not describe historical facts , including but not limited to , statements regarding : the proposed transaction between daiichi sankyo and ambit biosciences ; the expected timetable for completing the transaction ; strategic and other potential benefits of the transaction ; ambit biosciences’ product candidates , including regarding the therapeutic and commercial potential of quizartinib ; and any other statements about daiichi sankyo or ambit biosciences managements’ future expectations , beliefs , goals , plans , or prospects , are forward - looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward - looking statements . such risks and uncertainties include : the possibility that certain closing conditions to the transaction will not be satisfied ; that required regulatory approvals for the transaction may not be obtained in a timely manner , if at all ; the ability to timely consummate the transaction and possibility that the transaction will not be completed ; the ability of daiichi sankyo to successfully integrate ambit biosciences operations and employees ; the anticipated benefits of the transaction may not be realized ; risks related to drug development and commercialization ; and those additional factors discussed in ambit biosciences’ most recent quarterly and annual reports on forms 10 - q and 10 - k filed with the securities and exchange commission . daiichi sankyo and ambit biosciences caution investors not to place considerable reliance on the forward - looking statements contained in this press release . these forward - looking statements speak only as of the date of this document , and daiichi sankyo and ambit biosciences undertake no obligation to update or revise any of these statements .
company name : daiichi sankyo company , limited representative : sunao manabe , representative director , president and coo ( code no . : 4568 , first section , tokyo stock exchange ) please address inquiries to noriaki ishida , executive officer , vice president , corporate communications department telephone : + 81 - 3 - 6225 - 1126 urltoken
santa monica , calif . - - ( business wire ) - - kite pharma ( nasdaq : kite ) announced today that it has entered into a strategic partnership with daiichi sankyo co . , ltd . ( daiichi sankyo ) for axicabtagene ciloleucel ( approved usan for kte - c19 ) in japan . axicabtagene ciloleucel , kite ' s lead product candidate , is an investigational therapy in which a patient ' s t cells are engineered to express a chimeric antigen receptor ( car ) to target the antigen cd19 , a protein expressed on the cell surface of b - cell lymphomas and leukemias , and redirect the t cells to kill cancer cells .
daiichi sankyo was accused of paying kickbacks in the form of speaking events and meals . the u . s . department of justice claimed that some of the doctors’ speaking engagements were nothing but shams , that some physicians “spoke only to his or her own office staff , ” and that some audiences only included the doctors’ spouses .
daiichi officials agreed monday to pay $ 300 million to resolve patient suits over its blood - pressure treatments benicar , benicar hct , azor and tribenzor .
those cuts coincided with the loss of patent protection on the diabetes and cholesterol drug welchol , a $ 500 - million - plus seller for daiichi .
and just yesterday daiichi announced that 15 workers would be axed from its api plant in hiratsuka , and that the plant will shutter completely by september .
ds - 8201 is the lead investigational product in the antibody drug conjugate ( adc ) franchise of the daiichi sankyo cancer enterprise . antibody drug conjugates ( adcs ) are a type of targeted cancer medicine that deliver cytotoxic chemotherapy ( “payload” ) directly to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells . using daiichi sankyo’s proprietary adc technology , ds - 8201 is a smart chemotherapy comprised of a humanized her2 antibody attached to a novel topoisomerase i inhibitor ( dxd ) payload by a tetrapeptide linker designed to deliver enhanced cancer cell destruction upon release inside the cell and reduce systemic exposure to the cytotoxic payload ( or chemotherapy ) .
we are thrilled to partner with daiichi sankyo , a market leader in japan who shares our vision for engineered t - cell therapy and has strong development capabilities in oncology ,
said arie belldegrun , m . d . , facs , chairman , president , and chief executive officer of kite .
we have a strategic roadmap to commercialize axicabtagene ciloleucel globally while focusing kite ' s development and commercialization efforts in the united states and europe . daiichi sankyo ' s commitment to bring autologous t - cell therapy to patients in japan will complement our strategy and demonstrates the significant value in our pipeline , as well as the commercial potential for autologous t - cell therapy globally .
one interesting aspect of the cia is a recently instituted policy seen in endo pharmaceuticals’ 2014 settlement terms involving social media . daiichi must develop specific policies for “materials and information that may be distributed or made available by daiichi through social media and / or direct - to - consumer advertising . ” the cia states : “ [ t ] hese policies and procedures shall be designed to ensure that daiichi’s activities in this area and the information distributed or made available comply with all applicable federal health care program and fda requirements , and have been reviewed and approved by the applicable daiichi personnel before they are posted or disseminated . ”
as part of the settlement , daiichi sankyo also agreed to a corporate integrity agreement , which stipulates that the drug maker must implement compliance programs to prevent such illegal practices from occurring in the future . these sorts of agreements have become common in the pharmaceutical industry as the feds have pursued such charges in hopes of cracking down on illegal marketing .
the deal comes out of a whistleblower lawsuit filed by former daiichi sales representative kathy fragoules , who will get $ 6 . 1 million of the settlement .
daiichi allegedly paid the kickbacks to get doctors to prescribe its high blood pressure drugs azor , benicar and tribenzor , and its cholesterol - lowering drug welchol .
in its financials posted this morning , daiichi listed the six drugs , some of which we knew and others we didn’t , that didn’t make the grade .
the takamine memorial daiichi sankyo prize was established in november 2003 as part of the foundation’s 20th anniversary and in memory of the research work of dr . jokichi takamine , the first president ( march 1913– july 1922 ) of what was then sankyo co . , ltd . each year , the foundation presents this prize to an active researcher who is achieving remarkable feats in the progress and development of the life sciences , particularly in basic research for fields relating to the prevention and cure of disease as well as research with clear clinical applications .
daiichi sankyo is a large company with several different units . these include a u . s . unit headquartered in parsippany , new jersey . other units focus on vaccine research , non - prescription medications , non - drug medical products , and generic drug manufacturing . some are in japan , while others are in europe or the u . s .
i thank akira arimura , barbara beckman , douglas plymale , yutaka yamamoto , and the late agnes de mille for help in locating certain materials . special thanks to mamora arai of sankyo corporation .
“we are excited to evaluate if the combination of these two mechanisms of action – the ability of an anti - pd - 1 to harness the immune system and the potential of ds - 8201 to deliver chemotherapy directly to target cancer cells – may be able to improve the outcomes of patients with her2 - expressing advanced breast and bladder cancer , ” said antoine yver , md , msc , executive vice president and global head , oncology research and development , daiichi sankyo . “pursuing combination studies like this is at the core of the daiichi sankyo cancer enterprise strategy , as we are looking to maximize the potential of our proprietary antibody drug conjugate technology to help address the unmet needs of patients living with cancer . ”
although daiichi sankyo is headquartered in japan , it is a truly global pharmaceutical company . it provides medications for humans and animals , medical tools , equipment , food , and agrochemicals to more than 20 countries . although the current company has only existed since 2005 , the two that merged have been around for over 100 years , developing and designing drugs and technologies .
japanese drugmaker daiichi sankyo will pay $ 39 million to state and federal health programs , and a whistleblower , to settle claims it paid doctors kickbacks to prescribe some of its drugs , reuters reports . the settlement , the justice department said , stemmed from a whistleblower lawsuit filed by former daiichi sales representative kathy fragoules . she will get $ 6 . 1 million of the settlement . the drugmaker was accused of enticing doctors with speaking fees and lavish dinners , sometimes to speak only to their own staffs , the government contended . story
central to the plaintiffs’ case was their theory that daiichi sankyo took advantage of a “class effect . ” the complaint hones in on olmestartan , the principal active ingredient in the company’s drugs benicar and benicar hct , both fda - approved for hypertension . these drugs are part of a small class of marketed hypertension drugs known as angiotensin - ii receptor blockers ( arb’s ) .
arqule has developed tivantinib through a licensing , co - development , and co - commercialization agreement with daiichi sankyo covering the u . s . , europe , south america , and the rest of the world , excluding japan , china ( including hong kong ) , south korea , and taiwan . in those four countries , kyowa hakko kirin is arqule’s co - development partner .
as noted above , daiichi agreed to enter into a corporate integrity agreement with hhs - oig , which obligates the company to undertake compliance reforms for the next five years .
we continue to actively prioritize and manage our growing oncology portfolio to ensure that promising compounds are supported with appropriate resources , either within daiichi sankyo cancer enterprise or through strategic licensing agreements and partnerships ,
said antoine yver , md , msc , executive vice president and global head , oncology research and development , daiichi sankyo .
it ' s our obligation to bring innovative compounds to patients with cancer as quickly as possible , and we believe this agreement with an innovative u . s . partner will rapidly advance the development of this novel compound and potentially its availability to patients . boston pharmaceuticals has worked hard to develop a model that works for potential partners . we congratulate them on this success and look forward to continuing to explore similar collaborations in the future .
but in parallel to the internal cuts , daiichi has penned a string of oncology deals designed to give it a pipeline of candidates that can increase its success rate in the clinic . the most recent and high profile of these agreements is the deal with kite pharma , which gave daiichi the rights to car - t drug kte - c19 ( axi - cel ) in japan . kte - c19 is now spearheading an immuno - oncology pipeline that daiichi is hoping to flesh out through collaborations with companies including agonox and zymeworks .
“combination therapy with agents that target different and complementary pathways—in this case , the combination of a checkpoint inhibitor and innovative chemotherapy delivery—is a potential new approach for patients with difficult to treat cancers , ” said fouad namouni , m . d . , head of development , oncology , bristol - myers squibb . “we are looking forward to working with daiichi sankyo to investigate the synergies of these treatment methods . ”


linear acoustic is an american company based in lancaster , pennsylvania that develops technology and manufacturers equipment used by television stations , cable television and satellite television services providers , post-production facilities and other content services providers to control , measure , manage and monitor multi-channel digital audio .

the company has been especially active in areas related to automated upmixing and downmixing of multichannel broadcast audio , and with issues related to relative loudness of broadcast audio .

the company was founded in 2002 by tim carroll , who had previously worked as product manager for the professional audio division of dolby laboratories in san francisco .

while at dolby , carroll contributed to the development of dolby digital ( ac-3 ) and dolby e encoding systems for dvd and high-definition television ( hdtv ) applications .

christina carroll is the vice president and executive director of linear acoustic and is responsible for managing day-to-day company operations .

the company ’s products can be broadly broken down into three categories : loudness controllers designed to help television broadcasters maintain consistent audio levels ; monitors and meters that measure digital audio levels , including loudness ; and stand-alone encoding and transcoding products for handling the various data compression technologies commonly found in digital television plants .

the subject of controlling loudness in television broadcasts has garnered considerable publicity since the fcc moved to implement enforcement of the commercial advertisement loudness mitigation or calm act on december 13 , 2012 .

while consumer complaints about overly loud television commercials are almost as old as the medium itself , the calm act began as legislation was first sponsored by representative anna eshoo , a democratic congresswoman in california , in 2008 .

the law was passed in 2010 and went into full effect in 2011 and 2012 .

the linear acoustic aero line of audio processors effectively measures and manages shifts in loudness and controls discrepancies between program and commercial audio without unnecessarily degrading the quality of the audio or significantly affecting the dynamic range that adds impact to digital television audio .

when used in combination with a meter capable of measuring loudness by the itu-r bs .1770 standard ( or derivatives of this standard , such as ebu r128 ) u.s. broadcasters will be able to achieve calm compliance by effectively managing and monitoring audio levels .

linear acoustic also manufacturers the upmax 5.1-channel upmixer , which creates multi-channel surround sound audio from 2-channel ( stereo ) sources .

nbc utilized this product during the 2008 beijing summer olympics , and relied upon the company ’s aero.qc products during the 2010 vancouver winter olympics .

in 2008 , linear acoustic became part of the telos alliance , based in cleveland , ohio .

the telos alliance comprises telos systems , axia audio , omnia audio , and 25-seven systems that manufacture broadcast telephone systems , consoles and audio over ip gear , audio processors , and audio time management hardware for radio stations .

frank foti , founder of omnia audio , is the telos alliance ceo .

at the 2012 nab show in las vegas , linear acoustic announced a co-branding agreement with dolby laboratories under which the company will manufacture stand-alone dolby-centric professional products such as audio codecs and audio bitstream test tools .

linear acoustic

2008 tv technology – superior technology award – linear acoustic aeromax 5 . 1 - xl
linear acoustic president and founder , tim carroll , gives a brief history of television audio .
audio engineers suggested investigating equipment from linear acoustic for a solution . after a lot of research and the evaluation of numerous products from several manufacturers , they have determined that linear acoustic’s aero . 100 dtv audio processor was the correct solution .
linear acoustic offers a comprehensive lineup of loudness measurement and control products to help you achieve calm and r - 128 compliance .
renowned linear acoustic loudness control and upmixing for compliance and viewer - pleasing quality , but with incredible cost - savings for pcm - only applications .
a compact and space - efficient 1ru loudness management platform for hosting linear acoustic® aeromax® processing , upmax® - ii upmixing / downmixing , dolby® coding , and nielsen® watermark encoding .
linear acoustic was founded in 2001 with the introduction of the octimax 5 . 1 audio processor . with the onset of digital television came myriad problems involving loudness and digital audio control . linear acoustic turned their attentions to solving these problems at every stage of the digital audio chain and soon developed a product range that made digital broadcast sound and work as it should .
a 2ru loudness management platform with front panel controls and color display for hosting linear acoustic® aeromax® processing , upmax® - ii upmixing / downmixing , dolby® coding , and nielsen® watermark encoding .
newbay media’s tv technology magazine honored the telos alliance tv solutions group ( tvsg ) with a best of show award for its linear acoustic ams at the 2017 nab show held this week in las vegas . linear acoustic ams is a comprehensive solution for real - time authoring , rendering and monitoring of advanced audio programs for the atsc 3 . 0 digital television system .
linear acoustic ams authoring and monitoring system is a comprehensive solution for real - time authoring , rendering , and monitoring of advanced audio programs for the atsc 3 . 0 digital television system .
minnetonka audio and linear acoustic are both part of the foundation of the tv solutions group of the telos alliance . more information on the tv solutions group is available here . for general sales inquiries , contact inquiry @ urltoken . for television technical support , please e - mail support @ urltoken or call + 1 - 717 - 735 - 3611 . to locate a dealer for linear acoustic or other telos alliance brands , visit the telos alliance dealer directory .
“we’re honored to be recognized by newbay media with a best of show award for our linear acoustic ams , ” saidjohn schur , president , the telos alliance tv solutions group . “we created ams to deliver the full vision of an advanced consumer audio experience for digital television . ”
ams is equipped with linear acoustic apto , the state - of - the - art loudness adaptation technology designed to carefully control audio levels in a way that preserves the transients , sonic image and artistic intent of the source , while ensuring loudness consistency and compliance for any desired target .
audio over ip ( aoip ) connectivity via livewire + / aes67 enables enterprise - wide audio access . audio from any video source can be put on the aoip network using a wide variety of livewire + / aes67 compliant devices available from linear acoustic , axia audio , and other 3rd party vendors .
linear acoustic has been the go - to manufacturer of processors and meters for television networks and local stations worldwide for more than a decade , but their products definitely have a place on the production side as well . the aero . 100 has proven to be an invaluable tool for them since then .
the linear acoustic ams offers a web interface , which controls the interactive features of mpeg - h offered to the viewer . the web interface allows viewers to build presets for different listening experiences , enabling viewers to personalize their sound experience for optimal playback on any platform , from mobile devices to immersive home theaters .
audio over ip ( aoip ) has been embraced by the radio side of broadcasting for many years where the myriad advantages of networked audio via the livewire + aes67 standard is well known . now , aoip is available for television audio thanks to linear acoustic aero . soft™ . the linear acoustic sdi xnode de - embeds two separate hd / sd - sdi inputs , converts it to up to 16 channels of livewire + aes67 audio , makes it available for processing , upmixing , and encoding in the brand - new aero . soft processing engine , and then re - embeds the audio into two independent sdi outputs . this provides unmatched flexibility , scalability and channel density .
linear acoustic ams can be used in production to actively author and monitor metadata , or in other parts of the broadcast chain to monitor and validate audio streams containing a control track which were authored upstream . in both scenarios , ams is capable of outputting 15 - channels of discrete audio with a metadata control track , a 5 . 1 - channel rendered output , 2 - channel rendered output , and a dedicated monitoring output , all simultaneously .
aero . 8000 runs on the new linear acoustic aero . 8000 processing engine hardware . each processing engine is capable of handling up to eight amx processing instances and 16 stereo pairs of aes67 / livewire i / o . the eight amx instances can be any combination of amx5 . 1 ( 5 . 1 + 2 + 2 ) , amx2 . 0 ( 2 + 2 + 2 ) or amx5x2 ( 2 + 2 + 2 + 2 + 2 ) . all amx instances support sap / dvs , loro / ltrt downmix , local audio insertion , and optional audio description ( warble tone ) functionality . itu - r bs . 1770 - 3 or ebu r128 meters are present on each audio program output . linear acoustic crowd control™ , which eliminates viewer complaints about “missing” or “hard to hear” dialogue , is now available for both 2 . 0 - and 5 . 1 - channel sources .
linear acoustic ams authoring and monitoring system is a comprehensive solution for real - time authoring , rendering , and monitoring of advanced audio programs for the atsc 3 . 0 digital television system . the audio system in atsc 3 . 0 provides listeners with a personalized , immersive audio experience using next generation audio ( nga ) technologies , including mpeg - h . ams simultaneously delivers advanced audio for atsc 3 . 0 broadcasts and 5 . 1 - / 2 - ch audio for atsc 1 . 0 broadcasts .
among the many features that can be completed using the web interface are device configuration and status , monitoring control , input / output routing , audio mixing and object panning , loudness processing and more . linear acoustic ams also makes authoring an mpeg - h audio stream using the web interface as simple as assigning the 15 available mono inputs to the 10 available channel groups , providing full user control . additionally , the solution simultaneously delivers advanced audio for atsc 3 . 0 broadcasts and 5 . 1 / 2 - channel audio for atsc 1 . 0 broadcasts .
the ams web interface controls the interactive features of mpeg - h offered to the viewer . using smart metadata and linear acoustic apto loudness control , ams facilitates easy audio mixing and authoring operations , even in the most demanding production scenarios . individual audio elements are combined with user specified metadata to create immersive and personalized audio programs for the viewer . the ams web interface allows the authoring engineer to easily control the interactive features of mpeg - h offered to the viewer , and build presets for different listening experiences . this enables viewers to personalize their sound experience for optimal playback , from mobile devices to immersive home theatres .
in 2010 , linear received a technical emmy® for
the pioneering development of an audio / metadata processor for conforming audio to the atsc standard ,
and has provided upmixing , loudness metering , encoding products , and technical support for nbc’s coverage of the 2008 bejing summer games , the 2010 vancouver winter games , the london 2012 summer games , the 2014 sochi winter games , and most recently , the 2016 summer games in rio .
for three decades , the brands of the telos alliance have revolutionized radio and television by pioneering disruptive , cutting - edge audio technology with the goal of helping global networks and local stations produce better programming , improve audience engagement , and bolster ratings . the telos alliance is made up of six brands—telos ® systems , omnia ® audio , axia ® audio , linear acoustic ® , 25 - seven ® systems , and minnetonka™ audio—that raise the bar for quality and innovation in the radio and television industries . the telos alliance invented audio over ip for broadcast and contributed time and resources to the effort that led to the aes67 standard . headquartered in cleveland , ohio , usa , with additional offices and dealers around the world , the telos alliance offers an industry - leading five - year warranty , and backs users ' critical on - air needs with worldwide 24 / 7 round - the - clock support for all customers .
fighting ignorance since 1973 . ( it ' s taking longer than we thought . )
just when i get the tv volume adjusted to the optimum level , a commercial comes on and rattles the house like a sonic boom . who ' s the einstein who decided i should listen to commercials at a level loud enough to rupture my eardrums ?
rick graydear cecil : for as long as i can remember , home theater has had the same problem , namely , while the parts of a movie or tv show full of explosions are loud enough to strip varnish off a coffee table , dialogue at the same volume is barely comprehensible because it ' s too damn quiet . thus you either have to constantly adjust the volume or resign yourself to the possibility of permanent ear damage every time you watch an action movie . what ' s the deal ? dan rosenbluth
several audio techniques are at work here , two of which , interestingly , work in opposite ways . but the motive is the same : noise sells .
viewers have complained about loud tv commercials since the 1950s but advertisers paid no heed , figuring people couldn’t ignore your message if you screamed it in their ears . in the 1960s the fcc began warning broadcasters to lower the volume but made no serious attempt at regulation , and industry efforts to self - police didn’t accomplish much either .
things got worse in the era of digital tv , with improved technology greatly increasing the range of discernible sound volume , better known as dynamic range . eventually congress stepped in , passing the commercial advertisement loudness mitigation ( calm ) act in 2010 . the law directed the fcc to set advertising loudness standards for broadcasters , cable operators and other video distributors . by december 13 , 2012 , a commercial’s average sound level must be the same as the average loudness of the surrounding programming . the idea is that once you get the tv volume adjusted to a comfortable level you won’t risk having your eardrums ruptured by a sales pitch .
human ingenuity being what it is , the new rule may not entirely solve the problem . imagine a commercial skillfully interweaving tranquil footage of bunnies and butterflies with equal intervals of air raid siren - level noise . on average , the result is 100 percent fcc compliant . improved tv technology works both ways , however . check your owner’s manual to see if you have a function called automatic gain control , audio compression , or peak limiting . if you do , and you have the moxie to navigate through the byzantine array of menus and options on the average tv , they’ll enable you to control the peak noise level . my assistants una and fierra discovered their five - year - old television had two of the aforementioned options , so there’s a decent chance yours might too .
that brings us to the related problem of loud movies . increased dynamic range during regular programming was designed to enhance the vividness of the home theatre experience by reproducing the gamut of sounds you experience in real life . unfortunately for your hearing , the approximation of real life favored by hollywood tends to fixate on the whispers of the bedroom on the one hand and battling robots on the other .
action movies are particularly problematic . audio researchers found that whereas a typical episode of the sitcom friends had a nontaxing dynamic range of 6 . 6 “loudness units , ” the 1999 film the matrix had a range of 25 units . the eruption of noise during the matrix ‘s action sequences is part of its charm , of course , but such extreme dynamic range pushes the limits of what even the most sophisticated home system can reproduce , making it virtually impossible to find a comfortable volume level .
once again , though , technology is your friend . the dolby 5 . 1 system , for example , includes a “midnight mode” that compresses the dynamic range , lowering the sound peaks and raising the valleys to make a concussive soundtrack more listenable .
but here’s the surprising part . where the movie industry uses increased dynamic range to make more noise , the music industry uses dynamic range compression to do the same thing . dynamic compression is a major weapon in what’s been called the “loudness war , ” the steady increase in the volume of rock and pop music . going back at least to phil spector’s “wall of sound , ” music producers and engineers have always been trying to make their records sound bigger and more exciting than the competition’s , and one way of getting a song to jump off a jukebox is simply to make the recording itself louder .
because you can only turn the sound up so far before it becomes distorted , it eventually became standard practice to compress the dynamic range while cranking the gain until the song was uniformly loud — never mind the loss of sound quality . since the mid - 1980s the average loudness of cds has increased by a factor of 10 , a trend if anything exacerbated by the shift to mp3 players . how better to make a track really pop in shuffle mode than to torque its effective volume ? thus the curious paradox : a century of technological progress has culminated in popular recordings with less dynamic range than an edison phonograph cylinder of 1909 .
advertise on the straight dope ! your direct line to thousands of the smartest , hippest people on the planet , plus a few total dipsticks .
fusion aoip mixing console iq aoip mixing console radius 8 - fader aoip mixing console desq compact desktop ip - audio console raq rack - mount ip - audio console powerstation integrated console engine studioengine dsp mixing engine qor . 32 integrated console engine qor . 16 integrated console engine
aero . 2000 - audio / loudness manager aero . 100 - dtv audio processor aero . 10 - dtv audio processor aero . 8000
surcode for dolby pro logic ii surcode for dolby digital plus 5 . 1 encoder for adobe premiere pro cc surcode for dolby digital plus for avid surcode for dolby e surcode for dolby digital 5 . 1 standalone surcode encoder for dts - hd for compressor surcode for dts dvd / cd
the sdi xnode brings hd / sd - sdi signals into the axia livewire aoip ( audio over ip ) domain for use in audio processing or other applications .
enterprise - wide audio and loudness management deployed on a dedicated aero . 8000 processing engine , featuring the same algorithms as aero . 100 / 1000 / 2000 .
comprehensive itu - r bs . 1770 and ebu r128 loudness and peak level metering and logging for eight channels ( 5 . 1 + 2 ) plus downmix via aes or hd - sd / sdi audio .
drawing upon the success of its predecessors , upmax v4 - d produces engaging 5 . 1 - channel audio from two - and three - channel sources with ease and seamlessly transitions between discrete and upmixed audio .
a portable , handheld diagnostic tool that can monitor and generate dolby digital , dolby digital plus , dolby e , and pcm bitstreams anytime , anywhere .
using aero . 10 / 100 / 2000 / soft to create a ‘cleared’ feed .
an explanation of audio metadata , including a look at dialog level ( dialnorm ) , dynamic range control ( drc ) , and downmixing .
a more in - depth look at how audio metadata is created and distributed .
getting audio into the plant , moving it around , and encoding it in preparation for distribution .
what happens to the audio as it leaves the plant and gets to the viewer .
a detailed explanation of how audio coding works , both technically , and in relation to human hearing .
how the major terrestrial networks distribute multi - channel audio to their affiliate stations .
a closer look at how different networks have chosen to get their audio to the affiliates .
a high - level look at the status of multi - channel audio at the major networks .
now ! puts the latest broadcast audio technologies from the telos alliance in your hands .
html public
- / / w3c / / dtd xhtml 1 . 0 transitional / / en
urltoken
rep . anna eshoo , left , introduced the calm act in the house in june 2008 . … ( j . scott applewhite / associated… )
calm act , the commercial advertisement loudness mitigation law , which limits the volume of tv commercials , took effect thursday . it requires broadcasters to ensure that tv commercials maintain the same volume as the entertainment programming in which they are contained .
the legislative effort was begun more than four years ago by rep . anna g . eshoo ( d - menlo park ) , who was blasted by blaring ads on tv during a family holiday gathering .
“this has been a top consumer complaint for decades , ” eshoo said during a news conference thursday in washington . “i never dreamed that this would strike the chord that it did with the american public . ”
it would seem like an easy enough fix for broadcasters , but turning down the volume turned into a frustrating odyssey for lawmakers and regulators . the solution required a convention of engineers from around the world , rewriting broadcast standards and advances in audio technology . tv stations and cable and satellite tv operators have spent the last two years upgrading their equipment to better detect sound fluctuations .
normal listening levels are about 70 decibels for a television show , but levels can vary . the switch to digital television in 2009 made the problem worse because the higher fidelity sound made the commercials seem even louder , industry officials said .
sound metering equipment long used by broadcasters was not sensitive enough to discern fluctuations in volume .
“the old type of meter measured volts . they were just looking for technical indications of loudness , and those indications did not always relate to human perception , ” thomas lund , a development manager of denmark ' s tc electronic , said in a telephone interview . “levels and loudness are not always the same . ”
for example , high levels of sound for sustained periods come across to the ear as louder than for short duration . the old meters , lund said , did not measure that dimension of sound .
“the people who were creating the commercials learned how to exploit the meters and fly below the radar , ” lund said . the result : blaring ads .
the calm legislation marked an unusual case study of bipartisan support in washington . rep . eshoo introduced a one - page bill called the calm act in the house in june 2008 . two years later , a companion bill authored by sen . sheldon whitehouse ( d - r . i . ) unanimously passed the senate .
in december 2010 , the house passed the legislation and president obama signed the bill into law on dec . 15 , 2010 . the federal communications commission adopted its rules implementing the law a year ago , and provided a yearlong grace period so that stations could install the new equipment .
viewers can report super - loud commercials to the fcc on the agency ' s website or by calling 1 - 888 - tell - fcc ( 1 - 888 - 225 - 5322 ) .
hugh hefner will like the calm act . other boomers ? maybe . . .
cable industry needs to stop its noise over law on loud tv . . .
processing instances ( at least one is required ) providing real time adaptive wideband and / or multiband processing including an advanced itu limiter . output levels are consistent and compliant without compromising audio quality .
our hollywood - approved upmax ® - ii upmixing / downmixing algorithm creates engaging 5 . 1 - channel audio from 2 - channel sources and provides a downmix that is nearly indistinguishable from the original source .
available configurations for each instance include amx5 . 1 ( one 5 . 1 channel and two 2 - channel processing engines ) , amx2 . 0 ( three 2 - channel processing engines , one with 5 . 1 - channel downmixing ) and amx5x2 ( five 2 - channel processing engines ) . flexible signal routing is provided for main and secondary audio programs plus eas and local emergency audio insertion .
designed and built in the usa , the aero . 100 platform itself supports 8 audio pairs via sdi i / o with sdi video delay and 4 pairs via aes . failover bypass relays maintain signal continuity and dual auto - ranging power supplies enable redundancy and worldwide compatibility .
the included nfremote software provides comprehensive control over system settings and processing parameters remotely from any pc including access to the built - in http server for automated control or retrieval of loudness logs .
provides control over all system settings , processing and coding parameters plus extensive metering of signal presence , processing and coding activity , and audio loudness . system status reports physical i / o details along with system , power supply and environmental health . the remote application also delivers remote audio , up to 5 . 1 channels , to the user so that signal quality can be auditioned anywhere link bandwidth permits . http server is also included for simple get / set control of all parameters and status .
generates revenue - critical nielsen naes ii and the new nielsen watermark audience measurement codes . aero . 100 precisely inserts these signals for maximum code recovery after audio decoding and processing and before transmission encoding .
- ii 2 - channel to 5 . 1 - channel upmixing / downmixing with automatic detection and automatic downmix replacement
eight main inputs plus reference via 75 - ohm bnc female connectors . eight main outputs plus encoder output . all digital inputs are 75 ohm internally terminated , unbalanced . signal levels per smpte
auto - sensing hd / sd - sdi ( smpte 292m / 259m ) inputs , up to 1080i / 60 / 59 . 94 / 50hz . de - embed up to 16 channels from applied sdi signal , process and / or encode , re - embed up to 16 channels . supports smpte 2020 a and b vanc metadata
9 - pin female d connector ; 115 . 2 kbps ; pinout per smpte 207m ( rs - 485 ) ; designed to directly interface with dolby serial metadata ( smpte rdd6 )
windows® - compatible tcp / ip remote control included application for full setup and control , itu - r bs . 1770 metering for all programs , encoder statistics , and return audio for remote monitoring ( network speed permitting ) . http server allows get / set control from pc
dual power supplies , each rated at 100 - 264 vac , 50 / 60hz , auto - sensing , 150w max . total
net weight : 15 lbs . ( 6 . 80 kg ) , approximate .
north america : fcc and ce tested and compliant , power supply is ul approved .
europe : complies with the european union directive 2002 / 95 / ec on the restriction of the use of certain hazardous substances in electrical and electronic equipment ( rohs ) , as amended by commission decisions 2005 / 618 / ec , 2005 / 717 / ec , 2005 / 747 / ec ( rohs directive ) , and weee .
aero manual addendum 3 . 15 . 26 and 3 . 16 . 02 - snmp
aero manual addendum 3 . 15 . 26 and 3 . 16 . 02 - latency
hybrid dynamic range and loudness control with advanced itu limiter provide set - and - forget compliance and viewer - pleasing quality while included features deliver incredible cost - savings .
watermark encoding , and the ability to add a second processing instance are not required .
standard configurations are your choice of either a 5 . 1 + 2 + 2 or 2 + 2 + 2 channel configuration ; a 2 + 2 + 2 + 2 + 2 channel configuration is optional .
available in either a 5 . 1 + 2 + 2 or 2 + 2 + 2 channel configuration , or optionally , in a 2 + 2 + 2 + 2 + 2 channel configuration for processing up to 5 stereo programs
highest quality industry standard audio control has never been more affordable . aero . 10 is a fully - featured audio processor supporting up to ten channels of audio and featuring a processing engine identical to those in the aero . 100 / 1000 / 2000 products . tools such as loudness and dynamic range control , upmixing , downmixing , plus itu and ebu compliant loudness metering and logging makes the aero . 10 an extremely powerful solution for nearly any application at an extremely low cost .
to this , the aero . 10 adds a simple lcd front panel gui and stereo analog i / o . the headphone output has been designed to provide plenty of level even for difficult loads or quiet sources and is useful for checking audio or adjusting processing .
new with aero . 10 is the addition of stereo analog inputs and outputs which serve to support facilities amidst transition from analog to digital as well as interface with any analog device or signal path .
comprehensive tcp / ip remote provides control over all system settings and processing parameters plus extensive metering of loudness . system status reports physical i / o details along with system , power supply and environmental health . the remote application also delivers remote audio , up to 5 . 1 channels , so the user can audition signal quality anywhere link bandwidth permits . an http server is also included for simple get / set control of all parameters and retrieval of status and logging information . constantly active logging captures 7 . 5 day rolling weekly reports as well as specific time slots controlled by start / stop . loudness with multiple integration times as well as true peak measurements are captured and available for download .
designed and built in the usa , the lightweight and rugged single rack - unit aero . 10 is a solid investment in performance and flexibility . though all current features are standard , future options can be enabled by simply entering a factory provided key . failover bypass relays on all i / o maintain signal continuity and dual auto - ranging power supplies enable redundancy and worldwide compatibility .
available in either a 5 . 1 + 2 + 2 or 2 + 2 + 2 channel configuration with local / eas insertion , or optionally in a 2 + 2 + 2 + 2 + 2 channel configuration for up to 5 stereo programs .
dual upmax ii two - channel to 5 . 1 channel upmixers plus main channel downmixing , automatic bypass of discrete content ( in 5 . 1 + 2 + 2 configuration , downmix only in 2 + 2 + 2 processing configuration )
auto - sensing hd / sd - sdi ( smpte 292m / 259m ) inputs , up to 1080i / 60 / 59 . 94 / 50hz , access to audio and vanc metadata
dual power supplies , each rated at 100 - 264 vac , 50 / 60hz , auto - sensing , 100w max . total
one rack unit - 1 . 75”h x 19”w x 15 . 5”d ( 44 x 483 x 394 mm ) net weight : 9 lbs ( 4 kg ) ; shipping : 12 lbs
fan cooled . operating : 0 to 50 degrees c , non - operating –20 to 70 degrees c .
aero . 8000 is enterprise - wide audio and loudness management software for high - density applications featuring the trusted aeromax® adaptive wideband and multiband , multistage , itu - compliant , loudness control algorithm . an advanced itu limiter ( ai ) and itu bs . 1770 - 3 metering guarantees fast , accurate and measureable compliance with atsc and ebu r - 128 loudness recommended practices while maintaining the highest possible audio quality .
upmixing is provided by the hollywood - approved upmax® ii algorithm which delivers engaging 5 . 1 - channel audio from two - channel sources . automax™ detection and switching between 2 . 0 and 5 . 1 surround sources makes full time 5 . 1 surround output easy to achieve with viewer - pleasing results .
dolby® digital , dolby digital plus , and dolby e decoding and encoding are optionally available for each amx instance as is nielsen® watermark encoding for amx5 . 1 and amx2 . 0 instances .
an included comprehensive tcp / ip remote control application provides control over all system settings , processing and dolby digital coding parameters , per - channel signal presence , and loudness metering from any windows pc . multiple logs of lkfs loudness values , true peak , and dolby dialnorm and acmod values are provided for each program output . the remote control application also delivers remote audio monitoring so the user can audition signal quality anywhere link bandwidth permits . an http server is also included for log retrieval and provides control of all parameters and retrieval of status via network commands .
very high channel capacity software runs real - time on aero . 8000 processing engine
upmax ii automatic upmixing and downmixing with automax 5 . 1 surround / 2 . 0 detection and switching
extensive remote gui over ip control enables metering , control , and local audio monitoring ( up to 5 . 1 channels )
since 2003 , broadcast facilities have been using axia livewire aoip ( audio over ip ) technology to route hundreds of audio channels using standard ethernet switches , cables , and other components . with thousands of devices on the air every day , reliability is proven .
livewire is lightning fast , simple to implement , easy to manage , and now as livewire + , fully compliant with the aes67 standard and ready to incorporate new standards as they are developed . it significantly reduces the number of cables and wires needed to transport and share audio throughout the broadcast plant .
nearly any audio source – analog or aes , and now sdi – and myriad equipment from phone systems to codecs to satellite receivers – can be a part of the aoip network .
aeromax multistage adaptive wideband and multiband loudness and dynamic range control with itu - r bs . 1770 - 3 loudness metering
upmax ii two - channel to 5 . 1 channel upmixing and downmixing , automatically bypasses discrete content
aero . air user guide ( software v1 . 16 . 02 and later )
aero . air user guide ( software v1 . 18 . 01 2u and later )
aero . air user guide ( software v1 . 23 . 01 2u and later )
aero . lite aero . lite manual ( software v0 . 00 . 10 )
aero . qc aero . qc manual ( software v1 . 00 . 00 and later )
frame synchronizer ( la - 5448 ) la - 5448 manual ( software v1 . 00 . 21 and later )
metamax ( la - 5180 ) la - 5180 manual ( software v00 . 00 . 33 and later )
upmax : neo ( la - 5190 ) upmax : neo user guide ( software v00 . 57 and later )
authoring an mpeg - h audio stream using the web interface is as simple as assigning the 15 available mono inputs to the 10 available channel groups . from defining music beds , identifying independent objects , or grouping objects to be switched by the user , full control is available .
the telos alliance xnode family of aoip devices offer optional analog , aes / ebu , gpio logic , and sdi i / o , all with full livewire + aes67 audio over ip support .
telos alliance sdi xnodes can de - embed 3g / hd / sd - sdi inputs , extracting up to 16 channels of audio to the livewire + aes67 port . the audio can be re - embedded into the sdi output stream with full video delay compensation for each sdi input , ensuring that audio video synchronization is maintained .
using the web interface , up to 36 outputs may be configured , including 16 channels of authored audio plus control channels , up to 12 channels for monitoring , and two additional sets of output channels for rendered broadcast outputs .
- ii upmixing / downmixing algorithm creates engaging 5 . 1 - channel audio from 2 - channel sources and provides a downmix that is nearly indistinguishable from the original source .
designed and built in the usa , the aero . 2000 platform itself supports 8 audio pairs via sdi i / o with sdi video delay and 8 pairs via aes . failover bypass relays maintain signal continuity and dual auto - ranging power supplies enable redundancy and worldwide compatibility .
front panel controls , color display , and headphone output offer the ability to monitor and adjust the unit locally while the included nfremote software provides comprehensive control over system settings and processing parameters remotely from any pc including access to the built - in http server for automated control or retrieval of loudness logs .
capable of hosting one or two aeromax® processing instances in amx5 . 1 , amx2 . 0 or amx5x2 configurations
provides control over all system settings , processing and coding parameters plus extensive metering of signal presence , processing and coding activity , and audio loudness . system status reports physical i / o details along with system , power supply and environmental health . the remote application also delivers remote audio , including 5 . 1 channels , to the user so that signal quality can be auditioned anywhere link bandwidth permits . the built - in http server provides for simple get / set control of all parameters and status .
generates revenue - critical nielsen naes ii and the new nielsen watermarks audience measurement codes . aero . 2000 precisely inserts these signals for maximum code recovery – after audio decoding and processing and before transmission encoding .
48khz via aes dars ( or any aes signal applied to the ref in connector ) , aes in 1 , sdi , or from the internal 48khz clock ( standalone use only ) .
eight main inputs plus reference via 75 - ohm bnc female connectors . eight main outputs plus encoder output . eight additional channels of auxiliary digital i / o on db - 25 female connector . all digital inputs are 75 ohm internally terminated , unbalanced . signal levels per smpte 276m / aes - 3id - 2001 .
auto - sensing hd / sd - sdi ( smpte 292m / 259m ) inputs , up to 1080i / 60 / 59 . 94 / 50hz . de - embed up to 16 channels from applied sdi signal , process and / or encode , re - embed up to 16 channels . supports smpte 2020 a and b vanc metadata .
1 / 4’’ ( 6 . 35mm ) front panel connector with volume control .
9 - pin female d connector ; 115 . 2 kbps ; pinout per smpte 207m ( rs - 485 ) ; designed to directly interface with dolby serial metadata ( smpte rdd6 ) ethernet
gigabit ethernet via rj45 supports included tcp / ip remote control application ; http server included for get / set control of all parameters .
windows® - compatible tcp / ip remote control included application for full setup and control , itu - r bs . 1770 metering for all programs , encoder statistics , and return audio for remote monitoring ( network speed permitting ) . http server allows get / set control from pc front panel controls and indicators .
net weight : 13 lbs . ( 5 . 9 kg ) , approximate .
net weight : 18 lbs . ( 8 . 2 kg ) , approximate .
our aero™ series of transmission audio loudness managers includes aero . 2000™ , aero . one® , aero . lite™ , aero . mobile™ and the flexible high - density aero . 1000™ loudness platform .
the lq - 1000™ loudness quality monitor , lq - 1™ loudness meter and lambda™ digital audio and metadata monitor allow you to carefully and conveniently monitor audio , loudness level , and metadata throughout your station .
in addition , upmax™ produces completely downmix - compatible 5 . 1 channel audio from 2 channel audio sources , while the la - 5269™transcoder represents the ultimate in transcoding versatility .
call us at ( 352 ) 622 - 7700 . we are always happy to help !
we have access to a large variety of products . send us your request and will confirm we can quote your request within 24hrs .
each of our brands excel in their own areas and are frequently recognized by organizations within the industry . here is a look at some of the awards and honors that they have received :
2010 broadcast engineering award ibc 2010 – broadcast engineering pick hit award – aero . file
2000 16th annual technical excellence & creativity awards - minnetonka audio mx51 v2 . 0 - nominated for computer software and peripherals - outstanding technical achievement
newbay media’s best of show awards are evaluated by a panel of engineers and industry experts , and are selected based on innovation , feature set , cost efficiency and performance in serving the industry .
gbs alliance is an authorised distributor and system integrator for several international reputable brands in the am / fm / sw / tv broadcast equipment market .
has had a significant impact on broadcasters , as they now have to pay closer attention to their audio levels . however , compliance regulations have also reinforced the importance of correct audio levels to content creators and production houses as well .
most post - production company have already increased their attention towards audio , making sure that the content created is not only engaging , but also loudness - compliant . that focus has not been without its challenges .
this is relatively new ground for most people and companies of the broadcast chain . for many years , emphasis has been primarily on video , not audio , but nowadays , it’s not uncommon to see some pretty inconsistent audio levels between different programs , and even within a single piece of content . this has been a pondering issue for the industries .
a much needed audio measurement and processing device with sdi i / o , a good user interface and the ability to produce compliant audio with an emphasis on audio quality . that’s where the aero . 100 really stands out . the processed audio from it is not only compliant , but also is top - notch in quality , providing compelling and clear audio for the viewers at home .
among the more useful features of the aero . 100 in common application are the built - in itu - r bs . 1770 lfks meters . content runs though the unit without processing it , just to measure the levels . there are four separate meters , each with a user - selectable integration time , so they can look at short - term dynamics and the mid - and long - term averages at the same time . this lets the production crews identify exactly where the content is inconsistent or non - compliant , they can use aero . 100 processing to bring everything into compliance for their clients thus allowing them to facilitate their client’s needs with complete confidence .